Tamoxifen

證據等級: L5

預測適應症: 10 個

TAMOXIFEN: From ER-Positive Breast Cancer to Mammary Paget Disease

One-Sentence Summary

Tamoxifen is a selective estrogen receptor modulator (SERM) long established as a cornerstone hormonal therapy for estrogen receptor-positive (ER+) breast cancer treatment and prevention. The TxGNN model predicts it may be effective for Mammary Paget Disease, with 1 clinical trial and 13 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	ER-positive breast cancer (adjuvant treatment and prevention)
Predicted New Indication	Mammary Paget Disease
TxGNN Prediction Score	99.69%
Evidence Level	L3
Market Status	未上市 (No regulatory records in current dataset)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, tamoxifen is a selective estrogen receptor modulator (SERM) that competitively binds to estrogen receptor alpha (ERα), blocking estrogen-driven transcriptional activation in breast tissue. Its efficacy in ER-positive breast cancer has been extensively proven across landmark Phase 3 trials (NSABP B-14, ATAC, BIG 1-98), reducing recurrence by 25–30% over 10 years of adjuvant therapy.

Mammary Paget disease is a rare intraepithelial adenocarcinoma of the nipple-areola complex that, in 80–95% of cases, is accompanied by an underlying ER-positive invasive or in situ carcinoma. This strong biological co-occurrence provides the primary mechanistic bridge: by blocking ERα signaling in the associated underlying tumor, tamoxifen may suppress the carcinogenic milieu that sustains Paget cell populations. A case report of hormone receptor-positive metastatic extramammary Paget disease successfully treated with tamoxifen (PMID 34463889) provides direct proof-of-concept for ER-targeted therapy in Paget histology.

However, the direct responsiveness of Paget cells themselves — as distinct from the co-existing underlying carcinoma — to ERα blockade remains mechanistically uncertain. The TxGNN prediction likely reflects the model’s recognition of the strong ER biology shared between ER+ breast cancers and Paget disease, rather than evidence of autonomous Paget cell ER-dependence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00002920	Phase 3	Completed	313	Medroxyprogesterone acetate vs. observation to prevent tamoxifen-induced endometrial pathology in postmenopausal women with DCIS, lobular CIS, Paget’s disease of the nipple, Stage I–II breast cancer. Tamoxifen is the background therapy, not under evaluation; trial is not a direct Paget disease treatment study.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34463889	2022	Case Report	Investigational New Drugs	Successful tamoxifen treatment of HR-positive metastatic extramammary Paget disease; supports ER-directed therapy concept for Paget histology
14965622	2001	Case Report	Breast	Unusually extensive Paget’s disease of the nipple concealed for 10 years; response achieved with tamoxifen followed by electron arc radiotherapy; disease-free at 9 months
1648987	1991	Case Series	British Journal of Surgery	48-woman series over 13 years; treatment breakdown: 37 mastectomy, 10 cone excision, 1 tamoxifen alone; DCIS found in 45 operative specimens
25759627	2014	Meta-analysis	Breast Care	Local recurrence after mastectomy vs. breast-conserving surgery in Paget’s disease; total recurrence rate 20–40%; establishes standard-of-care surgical context
29694313	2018	Case Report	Il Giornale di Chirurgia	Male breast Paget disease; rare presentation with no established guidelines; underlying invasive ductal carcinoma common finding
19112575	2009	Case Report	Archives of Gynecology and Obstetrics	Synchronous vulvar and breast Paget disease with underlying adenocarcinoma; illustrates the systemic ER+ oncological context
12924421	2003	Case Report	Surgery Today	Synchronous bilateral breast cancer with Paget disease and invasive ductal carcinoma; demonstrates multifocal ER+ disease presentation
8955252	1996	Case Series	The American Surgeon	Review of 32 literature cases of male breast Paget’s disease; 50% present with palpable mass or positive nodes at diagnosis; tamoxifen noted in systemic therapy discussion
17319355	2006	Case Series	Nigerian Journal of Clinical Practice	8-case series at Nigerian teaching hospital; all female, mean age 47.6 years; late presentation common; provides epidemiological context
16277886	2005	Case Report	Clinical Breast Cancer	Paget’s disease as ipsilateral local recurrence after breast-conserving treatment in 2,181-patient cohort; highlights management complexity after initial ER+ breast cancer treatment

Market Authorization Information

No regulatory authorization records are available in the current dataset (0 licenses on file).

Data note: The absence of records reflects a query gap, not actual global unavailability. Tamoxifen (Nolvadex®, generics) holds established approvals in numerous jurisdictions for ER-positive breast cancer treatment and prevention. This dataset did not return matching regulatory records at the time of query.

Cytotoxicity

Tamoxifen meets the antineoplastic classification criteria: it is indicated for breast cancer (malignant condition) and is categorized as a selective estrogen receptor modulator with anti-tumor activity.

Item	Content
Cytotoxicity Classification	Targeted hormonal therapy — Selective Estrogen Receptor Modulator (SERM); non-conventional cytotoxic (not a DNA-damaging chemotherapy agent)
Myelosuppression Risk	Low (tamoxifen does not cause clinically significant myelosuppression at standard doses)
Emetogenicity Classification	Low
Monitoring Items	Endometrial thickness / annual gynecological exam (especially postmenopausal women); liver function tests; coagulation parameters (VTE risk assessment); ophthalmologic exam at high-dose or prolonged use; bone mineral density (premenopausal patients on long-term therapy)
Handling Protection	Standard precautions per institutional policy for hormonal antineoplastic agents; not classified as a conventional hazardous cytotoxic requiring full PPE containment, but reproductive toxicity warrants appropriate handling by pregnant staff

Safety Considerations

Please refer to the package insert for safety information.

Detailed prescribing information was not retrieved in this dataset (Data Gap DG001). Key known risks based on drug class include: endometrial cancer risk (primarily postmenopausal women), venous thromboembolism, menopausal symptoms (hot flashes, vaginal discharge), and rare retinal toxicity. CYP2D6 poor metabolizer status impairs conversion to active metabolite endoxifen and may reduce efficacy.

Conclusion and Next Steps

Decision: Hold

Rationale: While the biological rationale linking tamoxifen to mammary Paget disease is coherent — given that 80–95% of cases involve an underlying ER-positive carcinoma — direct clinical evidence for tamoxifen in Paget disease itself remains confined to isolated case reports and one Phase 3 trial where Paget’s patients were enrolled as a minor subgroup. The evidence does not yet meet the threshold for a formal repurposing designation; this is best framed as an investigational signal warranting prospective evaluation.

To proceed, the following is needed:

Prospective registry study or dedicated pilot trial in mammary Paget disease evaluating tamoxifen response (particularly in patients with confirmed HR-positive underlying carcinoma)
Histopathological ER/PR receptor characterization of Paget cells directly (not only the underlying carcinoma) to determine autonomous ER-dependence
Mechanistic clarification of whether tamoxifen suppresses Paget cells via ERα in the epidermal compartment or exclusively through control of the underlying tumor
Retrieval of detailed MOA data from DrugBank (Data Gap DG002)
Retrieval of TFDA/FDA package insert warnings and contraindications (Data Gap DG001) to complete safety screening before any clinical protocol design
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.